Abiopharma

🔍 Mottola Frank (Executive)

Company: SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Report Date: 2026-03-06

Detailed Transactions and Holdings:

• Acquired 3,750 shares of Common Stock (Direct)
  Date: 2026-03-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 21,856.00 | transaction_form_type: 4
• Sold 1,793 shares of Common Stock at $54.73 per share (Direct)
  Date: 2026-03-06 | Code: F | equity_swap_involved: 0 | shares_owned_after: 20,063.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,623 shares of Common Stock at $53.65 per share (Direct)
  Date: 2026-03-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 18,440.00 | transaction_form_type: 4
• Sold 3,750 shares of Performance Share Unit (Derivative)
  Date: 2026-03-06 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
• F2: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.